Safety and efficacy outcomes after intranasal administration of neural stem cells in cerebral palsy: a randomized phase 1/2 controlled trial

Table 3 Clinical changes of scales between groups

	Treatment group	Control group	P value
FMFS
Baseline	24.00 ± 15.85	26.50 ± 14.99	0.701
24 M	36.56 ± 17.86^#	24.56 ± 14.25^#	0.136
SS
Baseline	25.50(8.75–45.00)	26.00(15.13–46.75)	0.546
24 M	48.50(23–53.50)^#	27.50(13.75–44.63)^#	0.238
LAS
Baseline	23.50(11.13–50.63)	31.75(13.50–48.25)	0.841
24 M	54.00(22.50–56.00)^#	27.25(15.00–51.88)^#	0.238
EAS
Baseline	17.50(8.00–51.75)	29.25(10.75–50.50)	0.886
24 M	54.00(19.00–56.00)^#	34.00(11.75–52.63)^#	0.395
GMFM-88-A (Lying and Rolling)
Baseline	51(44.5–51)	49(38.5–49.5)	0.259
24 M	51(51–51)	48(36.5–50.5)	0.041^*
GMFM-88-B (Sitting)
Baseline	44.5(26.25–57)	46.5(29–56.5)	0.796
24 M	59(56–60)^#	41.5(21.5–57.75)	0.051
GMFM-88-C (Crawling and Kneeling)
Baseline	18.5(6.75–33)	7(0–35.25)	0.625
24 M	40(35–42^)#	5(0–32.25)	0.016^*
GMFM-88-D (Standing)
Baseline	17(7.5–23.5)	7.5(0–18.5)	0.172
24 M	27(25–31)^#	3.5(0–17)	0.002^*
GMFM-88-E (Walking, Running and Jumping)
Baseline	11(2–25.25)	4.5(0–16.25)	0.285
24 M	31(12–47)^#	1.5(0–12)	0.007^*
GMFM-88-TOTAL
Baseline	52.41 ± 24.44	47.43 ± 27.30	0.644
24 M	74.95 ± 23.84^#	41.94 ± 24.50	0.009^*
ADL
Baseline	34.54 ± 20.90	40.65 ± 31.72	0.574
24 M	61.68 ± 26.16^#	32.81 ± 20.09	0.018^*
SDSC
Baseline	49.43 ± 14.27	47.90 ± 19.81	0.828
24 M	39.14 ± 9.77^#	47.50 ± 18.54	0.164

Data are summarized as the mean ± SD (standard deviation). GMFM: Gross Motor Function Measure; ADL: Activity of Daily Living; SDSC: Sleep Disturbance Scale for Children; FMFS: Fine Motor Function Scale; SS: Sociability Scale; LAS: Life Adaptability Scale; EAS: Expressive Ability Scale; 24 M: 24 months after treatment
*P < 0.05 (compared with Control group); #P < 0.05 (compared with Baseline)

ISSN: 1757-6512